Smith & Nephew plc Receives Neutral Rating from JPMorgan Chase & Co. (SN.)
Smith & Nephew plc (LON:SN.)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday, Analyst Ratings Network.com reports. They currently have a GBX 740 ($11.87) price target on the stock.
A number of other firms have also recently commented on SN.. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Tuesday, October 1st. They now have a GBX 830 ($13.32) price target on the stock. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Wednesday, September 25th. They now have a GBX 775 ($12.43) price target on the stock, up previously from GBX 750 ($12.03). Finally, analysts at Societe Generale cut their price target on shares of Smith & Nephew plc from GBX 695 ($11.15) to GBX 660 ($10.59) in a research note to investors on Monday, September 9th. They now have a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. Smith & Nephew plc presently has an average rating of “Hold” and a consensus target price of GBX 772.86 ($12.40).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.